^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MIL62

i
Other names: MIL62, MIL 62, MIL-62
Associations
Company:
Beijing Mabworks Biotech
Drug class:
CD20 inhibitor
Related drugs:
Associations
1d
A Clinical Study of MIL62 in Primary Membranous Nephropathy (clinicaltrials.gov)
P3, N=150, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Dec 2024 --> Mar 2025
Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
cyclosporine • MIL62
1d
A Clinical Study of MIL62 in Primary Membranous Nephropathy (clinicaltrials.gov)
P1/2, N=120, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Nov 2024 --> Mar 2025
Trial primary completion date
|
cyclophosphamide • cyclosporine • MIL62
2d
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
P1/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Phase classification: P1b/2 --> P1/2 | Trial primary completion date: May 2024 --> Jan 2024
Phase classification • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
lenalidomide • MIL62
2d
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Mar 2024 --> Mar 2025
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • MIL62
1year
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial completion date: May 2023 --> May 2025 | Trial primary completion date: Jan 2023 --> May 2024
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
lenalidomide • MIL62
over1year
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Mar 2023 --> Mar 2024
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • MIL62
2years
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=43, Active, not recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Active, not recruiting | N=120 --> 43
Enrollment closed • Enrollment change
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Yinuokai (orelabrutinib) • MIL62
2years
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Jun 2022 --> Jan 2023
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
lenalidomide • MIL62
almost3years
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • MIL62
over3years
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=120, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Not yet recruiting --> Recruiting | N=50 --> 120 | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Dec 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Yinuokai (orelabrutinib) • MIL62
over3years
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
lenalidomide • MIL62
over3years
A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas (clinicaltrials.gov)
P1, N=27, Completed, Beijing Mabworks Biotech Co., Ltd. | Active, not recruiting --> Completed
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
MIL62
over3years
New P3 trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • MIL62